The 230-kDa merozoite antigen of the murine malarial parasite Plasmodium yoelii provides a potential model system for the development of a protective erythrocytic stage vaccine. To characterize this antigen at the molecular level, isolated P. yoelii 17XL DNA was used to construct a genomic library in the expression vector Agtll. A monoclonal antibody, mAb 302, which passively protected mice against P. yoelii challenge infection, was used to identify a Agtll recombinant clone encoding a portion of the 230-kDa antigen of this parasite. Using this clone as a probe, we identified an mRNA of 7.6 kilobases by RNA blot analysis. Nucleic acid sequence analysis of the clone showed that the epitope recognized by the protective mAb 302 is encoded by the 3' portion of the gene for the 230-kDa antigen. The deduced amino acid sequence revealed that this antigen also contains the tandemly repeated tetrapeptide Gly-Ala-Val-Pro, a series of 10 cysteine residues located within the terminal 110 amino acids, and a potential membrane anchor of 18 hydrophobic residues. Comparison of this C-terminal sequence with the carboxyl segment of the 195-kDa merozoite antigen of Plasmodiumfalciparum revealed nucleic acid and amino acid sequence similarities ranging from 40% to 70%. The localization of a B-cell epitope recognized by the protective mAb 302 to this carboxyl region of the P. yoelii antigen, combined with the limited strain variability in this region of the homologous 195-kDa antigen of P. falciparum, has implications for the development of an effective erythrocytic stage malarial vaccine.
The development of an anti-malarial vaccine has focused on the identification and characterization of plasmodial antigens inducing protective immune responses. During infection, the parasites progress through various developmental stages, presenting the host with a complex array of antigens. The elicited immune responses are equally complex, stage specific, and involve both humoral and cell-mediated mechanisms (1, 2) . Despite this diversity, sporozoite, erythrocytic, and gametocyte stage-specific antigens have emerged as potential vaccine candidates (3) .
During the erythrocytic phases of development, a class of high molecular weight merozoite surface antigens has been identified in rodent (4, 5) , simian (6) , and human (7) plasmodial species. These surface proteins may be involved in merozoite invasion of erythrocytes (8) , and host immune responses directed toward them have provided significant levels of protection against challenge infection (9) (10) (11) (12) . Consequently, evaluation of these antigens as vaccine components has led to an increasing need for the development of experimental model systems.
Previously, this laboratory reported the production of a monoclonal antibody, mAb 302, which protected mice passively against challenge infection with Plasmodium yoelii (13) . This antibody recognized specifically a 230-kDa merozoite antigen, PY230. Prior evidence indicated that this antigen is homologous to a 195-kDa merozoite antigen of the human malarial parasite Plasmodiumfalciparum, PF195 (5) . We now report the cloning and sequencing of a 2-kilobase (kb) portion of the PY230 gene encoding the B-cell epitope recognized by the protective mAb 302. The epitope is located in the carboxyl-terminal portion of the molecule, which contains regions of both nucleic acid and protein sequence similarity with the 195-kDa P. falciparum antigen.* MATERIALS AND METHODS Experimental Infections. Male BALB/c or C57BL/6 mice, 6-10 weeks old, were purchased from The Jackson Laboratory. Infections were initiated by injection of parasitized erythrocytes of the lethal 17XL or nonlethal 17X strains of P. yoelii and were monitored as described (13) .
Antibodies. Hyperimmune antisera against P. yoelii (HIS)
were obtained from animals infected repeatedly with the nonlethal P. yoelii 17X (14) . mAb 302 was obtained from either tissue culture supernatants or from ascites fluids of mice carrying the mAb 302 hybridoma tumor. Polyclonal antisera against the PY230 antigen were generated by immunization of BALB/c mice with parasite antigens complexed with mAb 302 in Freund's complete adjuvant. These immune complexes were prepared by immunoprecipitation of PY230 from a solubilized preparation of P. yoelii 17XL-infected erythrocytes. Antisera were collected following subcutaneous immunization at four monthly intervals.
Library Construction. Parasitized blood from 50 C57BL/6 mice was collected on day 6 postinfection with P. yoelfi 17XL, when parasitemias averaged 40%. Leukocytes were removed from the pooled blood by passage over columns of microcrystalline cellulose (15) . Parasite DNA was extracted as described (16) Recombinant Agtll lysogens were generated by infecting the E. coli strain Y1089 and /8-galactosidase fusion protein expression was induced as described (17) . Bacteria pelleted from 1-ml culture samples were resuspended in NaDodSO4/ polyacrylamide gel sample buffer (0.125 M Tris HC, pH 6.8/ 2.5% NaDodSO4/5.0% 2-mercaptoethanol), boiled, and electrophoresed on 7.5% NaDodSO4/polyacrylamide gels according to Laemmli (18) . 83-Galactosidase fusion proteins were identified by immunoblot analysis (19, 20) using either HIS or mAb 302. Bound antibody was detected by using 125I-labeled protein A followed by autoradiography.
RNA Blot Analysis. Parasitized erythrocytes were isolated from the blood of P. yoelii 17XL-infected mice as described above, and lysed in phosphate-buffered saline (10 mM sodium phosphate/150 mM sodium chloride, pH 7.4) containing 0.1% glucose and 0.01% saponin. RNA was extracted from the pelleted parasites by the guanidinium isothiocyanate/cesium chloride method, and separated into poly(A) + and poly(A)-fractions by oligo(dT)-cellulose column chromatography (21) . This RNA was electrophoresed through agarose gels containing formaldehyde and transferred to nitrocellulose (21 (22) . A series of clones containing overlapping deletions of each of these subcloned fragments was generated by either controlled exonuclease III digestion of isolated replicating form DNA (23) or by the rapid deletion method of Dale et al. (24) using single-stranded phage DNA. Template DNA from JM101-infected cells was isolated (22) and sequenced by the Sanger dideoxy chain-termination method (25) rounds of screening, two recombinants, A1.4 and A6.3, remained positive. That these clones contained PY230 coding sequences was confirmed by using a polyclonal antiserum raised against the PY230 antigen.
Recombinant phage A1.4 and A6.3 were lysogenized in the E. coli strain Y1089, grown up, and induced; bacterial extracts were separated on 7.5% NaDodSO4/polyacrylamide gels. Immunoblots of these gels identified in both recombinants a j3-galactosidase fusion protein of 190 kDa when probed with either HIS (Fig. 1, lanes 3 and 4) or mAb 302 (lanes 7 and 8 ). An additional recombinant protein of 138 kDa, presumably a degradation product, was detected only with HIS. These recombinant proteins were not detected in extracts of Y1089 cells alone (lanes 1 and 5) or Y1089 cells lysogenized with wild-type Agtll (lanes 2 and 6). Since the 3-galactosidase protein sequence accounts for 114 kDa of the fusion protein, these clones encode =76 kDa of the PY230 antigen, including the determinant recognized by mAb 302.
Identification of PY230 mRNA. Isolation and digestion of phage DNA from A1.4 and A6.3 showed both to contain an EcoRI insert of 4.3 kb. Since the isolated clones appeared to be identical, only the insert of A6.3 was subcloned into the EcoRI site of the plasmid pUC9. Subsequently, a 1.85-kb EcoRI/EcoRV fragment of this insert was radiolabeled by nick-translation and hybridized to an RNA blot of P. yoelii 17XL RNA, separated into poly(A)+ and poly(A)-fractions. This probe detected a 7.6-kb mRNA present in both the total RNA preparation (Fig. 2, lane 1) TCFTAT ATA TAT TTT AAA AGT TGT ATA GTA CAT TTG AAA TAT ATA TTC TGG CAT AAA TTG TAT ATT TTT TAA TAT AAA AAA 2160   2161 AAA AAA TAT ATA TAA TTT TTA ATA AAT ATT TTT AAA TAA ATG TAT ATG TAT ATA GTG TTA GGA AAT TTT GTA TGA GTT TAA AAT ATG ATA 2250 Proc. Natl. Acad. Sci. USA 85 (1988) presumably functioning as a membrane anchor sequence (26) . Following the first in-frame termination codon, the sequence contains multiple termination codons in all three reading frames. The A+T content is similar to that previously found in other plasmodial genes (27) , 71% in the coding region and 88% in the 3' untranslated segment. Also noteworthy is a series of 10 cysteine residues located in the final 110 amino acids of the sequence. Further upstream, the sequence contains the tetrapeptide Gly-Ala-Val-Pro repeated tandemly six times. The deduced amino acid sequence also shows six potential sites for N-linked glycosylation, although it has proven difficult to demonstrate carbohydrate on this molecule (28) . Most significantly, however, these data show that the epitope recognized by the protective mAb 302 is located in the carboxyl-terminal 76 kDa of the PY230 antigen.
Comparison Between the C-Terminal Portion of PY230 and the 195-kDa Antigen of P. fakiparum. Computer-assisted analysis aligned this C-terminal sequence of PY230 with the carboxyl segment of the homologous 195-kDa antigen of the Wellcome strain of P. falciparum. Nucleic acid sequence similarity ranged from -40% to -70% ( Fig. 4A ) with similar levels in the protein sequence, considering conservative amino acid substitutions (Fig. 4B) . Interestingly, a terminal series of cysteine residues was conserved in both antigens; specifically, 10 of the final 110 amino acids in PY230, and 11 of the final 100 amino acids in PF195. Furthermore, alignment of the protein sequences of these antigens showed that 9 of the 10 PY230 cysteine residues were located in a similar position relative to those of PF195.
DISCUSSION
Through the construction of a P. yoelii 17XL Agtll expression library, we have cloned and sequenced the portion of the PY230 gene encoding the epitope recognized by the protective mAb 302. Our data show that this epitope is located in the carboxyl-terminal 76 kDa of the PY230 antigen. The relationship between this PY230 antigen and the 195-kDa antigen of P. falciparum has been strengthened by the demonstration of nucleic acid and protein sequence homology in the C-terminal sequences.
Previous studies in animal models have implicated this high molecular weight class of blood stage antigens in the induction of protective immune responses. Specifically, the passive administration of mAb 302 provided dramatic in vivo protection against P. yoelii infection (13) . In addition, purified preparations of PY230 have been used successfully to immunize mice against lethal challenge (9, 10) . mAb against the analogous 250-kDa antigen of Plasmodium knowlesi blocked merozoite invasion of rhesus monkey erythrocytes (6) . Consequently, the homologous 195-kDa merozoite antigen of P. falciparum has drawn considerable attention as a vaccine candidate. In a recent report, Aotus monkeys immunized with this antigen emulsified in Freund's complete adjuvant were totally protected from lethal challenge infection with the homologous parasite (12) .
Immunologic (29) , with three of these mapping to the carboxyl terminus of the molecule (36) . In addition, one mAb recognizing a determinant in this region has been shown to block merozoite invasion in vitro (37) . These epitopes are detected on a glycosylated 40-to 50-kDa processed fragment of PF195, shown to be expressed on the merozoite surface (36) (37) (38) . Available data also suggest that a portion of this peptide is retained by the parasite following schizont rupture and subsequent invasion of erythrocytes (34, 38) . Furthermore, studies at the nucleic acid level indicate that portions of the region encoding the C terminus appear conserved between various P. falciparum isolates (39, 40) .
The role of the C-terminal portion of these merozoite plasmodial parasite point to a need for the conservation of these sequences between species. Particularly, the preservation of nine C-terminal cysteine residues in homologous positions in both antigens suggests that this region of the molecule may provide some structural domain necessary for parasite development. This, combined with the lack of variability in this region between P. falciparum isolates, has significant implications for vaccine development. Using the P. yoelii murine model, we will be able to test, in vivo, the potential of this region to induce protective responses as well as the factors regulating these responses.
